Newark, DE, Nanjing CN – Dec 9, 2021. Biosion Inc. (“Biosion”), a global, clinical-stage biotech company, today announced completion of a 200 million RMB preB+ financing round (including preB 2nd tranche financing) to accelerate discovery and global development of its innovative biologics portfolio targeting immunologic and cancer diseases. The financing was led by 3E Bioventures Capital, joined by Chase Capital. Concurrent with the financing, Mr. Lei Liu, the Director of 3E Bioventures Capital will join Biosion’s Board of Directors. Index Capital acts as the sole financial advisor for the current round of financing.

“We are pleased to welcome 3E Bioventures Capital – a prestigious professional bio-venture capital firm – to join our effort in building our differentiated preclinical and clinical development portfolio, our global biologics development team and to further enable our strategy to be a leading “In Global For Global” biotech company” said Dr. Mingjiu Chen, Founder, Chairman and CEO of Biosion.

Dr. Karen Liu, Partner of 3E Bioventures Capital, said: “We believe GLOBALIZATION is the big theme for the next generation of biopharma. The capability of accessing a global talent pool, leveraging territorial clinical resources, and navigating through regional regulatory barriers is key to translating novel science from concept to product. We are excited and confident that Biosion is on the launchpad to lead this wave of industry change with its world-class leadership team.”

Through recent significant enhancement of the Executive Leadership team, Advisory Board and Global Development team, Biosion is now poised to substantially accelerate global clinical development efforts of its innovative biologics pipeline.